> Dr Reddy's Laboratories has launched in the U.S. its generic version of Pfizer's ($PFE) cholesterol-lowering drug Caduet. Story
> California-based Codexis ($CDXS), a developer of biocatalysts for the pharma and chemical industries, has sold a lab in Hungary to Intrexon ($XON) which that California company intends to use in API production. Release
> Contract manufacturer Cytovance Biologics in Oklahoma City, has expanded its agreement with Texas-based Precision Biologics, to provide technology transfer and additional cGMP manufacturing services for Phase II clinical trials. Release
> Supplement company Pure Edge Nutrition, of Toms River, NJ, is voluntarily recalling three lots of products because they may contain either the unapproved painkiller sibutramine or a combination of sibutramine and the unapproved laxative phenolphthalein. Release
> India's Lupin has acquired for an undisclosed amount Mexico's Laboratorios Grin, a drugmaker specializing in ophthalmic products. Story
And Finally... Novartis' ($NVS) Sandoz unit has received approval in Japan to sell there a biosimilar of Kyowa Hakko Kirin's cancer med Gran. Release